Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Single Ascending Dose Safety, Pharmacokinetic and Pharmacodynamics Study of SEL-212 in Subjects With Elevated Blood Uric Acid

NCT02648269 is registered in ClinicalTrials.gov with Selecta Biosciences, Inc. as lead sponsor.

NCT NCT02648269
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02648269 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Single Ascending Dose Safety, Pharmacokinetic and Pharmacodynamics Study of SEL-212 in Subjects With Elevated Blood Uric Acid
Lead sponsor
Selecta Biosciences, Inc.
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2015
Completion date
December 31, 2016
Enrollment
63 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

gout